Wegovy Australia Cost
Wegovy Australia Cost: What You Will Pay in 2026 and How to Get a Prescription
TL;DR
Wegovy (semaglutide 2.4 mg) costs between $350 and $500 per month in Australia when prescribed privately. The medication is not yet listed on the PBS, although the PBAC recommended it in January 2026, and price negotiations with Novo Nordisk are underway. Any Australian GP can prescribe Wegovy for eligible patients without a specialist referral. During the 16-week dose escalation period, monthly costs are lower because starting doses are cheaper than the 2.4 mg maintenance dose.
Wegovy is one of the most searched prescription weight loss medications in Australia, and the question patients ask most often is a simple one: how much does it cost? The answer depends on your dose, your pharmacy, and whether the medication eventually receives PBS subsidisation.
This guide breaks down the current cost of Wegovy in Australia, explains the dose escalation pricing you will encounter during your first 16 weeks, outlines the PBS listing timeline, and walks through the prescription pathway so you understand exactly what to expect before your first consultation. If you are comparing Wegovy with other GLP-1 medications like Mounjaro or Ozempic, this post will give you a clear pricing baseline.
What Is Wegovy and How Does It Work for Weight Loss?
Wegovy is the brand name for semaglutide at a 2.4 mg weekly dose, manufactured by Novo Nordisk. It was approved by the Australian Therapeutic Goods Administration (TGA) in August 2024 for chronic weight management in adults with obesity or who are overweight with at least one weight-related health condition.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. These medications work by mimicking a hormone your body produces naturally after eating. The medication slows gastric emptying, meaning food stays in your stomach longer, and it acts on appetite centres in the brain to reduce hunger and increase the feeling of fullness after meals.
The same active ingredient appears in Ozempic at a lower dose (1 mg), which is approved by the TGA for the treatment of type 2 diabetes. Wegovy delivers a higher dose specifically optimised for weight management. These are two distinct products with different TGA indications, different dosing schedules, and different prescribing criteria.
How Much Does Wegovy Cost Per Month in Australia?
At the maintenance dose of 2.4 mg per week, Wegovy costs between $350 and $500 per month in Australia when prescribed privately. The exact price varies by pharmacy, location, and whether you are purchasing through a telehealth platform or in-store.
Here is what you can expect to pay at each stage of treatment:
Dose escalation period (weeks 1 to 16): You will not start at the full maintenance dose. Wegovy uses a 16-week dose escalation schedule to help your body adjust and reduce the likelihood of gastrointestinal side effects. During this period, monthly costs are lower because the starting doses are cheaper.
Weeks 1 to 4: 0.25 mg per week (approximately $270 to $350 per month)
Weeks 5 to 8: 0.5 mg per week (approximately $280 to $370 per month)
Weeks 9 to 12: 1 mg per week (approximately $300 to $400 per month)
Weeks 13 to 16: 1.7 mg per week (approximately $320 to $430 per month)
Week 17 onward: 2.4 mg maintenance dose (approximately $350 to $500 per month)
First year total estimate: Including the cheaper escalation months, your first year on Wegovy will cost approximately $3,800 to $5,200, depending on your provider and pharmacy. Subsequent years at the maintenance dose cost approximately $4,800 to $5,500 per year.
Consultation fees: Your initial GP or telehealth consultation will typically cost $50 to $150 on top of the medication price. Some telehealth platforms include the consultation fee in their monthly medication price; others charge it separately.
These are approximate costs based on publicly available pricing from Australian pharmacies and telehealth providers. Prices change, so always confirm the current cost with your pharmacy or prescriber before starting treatment.
Is Wegovy on PBS? Current Listing Status and Timeline
Wegovy is not currently listed on the Pharmaceutical Benefits Scheme (PBS). However, progress toward a listing is underway.
In January 2026, the Pharmaceutical Benefits Advisory Committee (PBAC) issued a positive recommendation for Wegovy to be added to the PBS. This followed an extensive review of the SELECT clinical trial data, which demonstrated that semaglutide 2.4 mg reduced major cardiovascular events by 20% in patients with established heart disease and obesity.
A positive PBAC recommendation is necessary but not sufficient for PBS listing. The next step is price negotiation between the Australian Government and Novo Nordisk. These negotiations are currently underway, and Health Minister Mark Butler has publicly committed to working with Novo Nordisk to finalise the listing.
Who will qualify if Wegovy is PBS-listed? The recommended PBS criteria are narrower than the general TGA prescribing criteria. To access a subsidised prescription, patients would need to meet all of the following:
BMI of 35 or greater (or 32.5 or greater for patients of Asian, Aboriginal, or Torres Strait Islander background)
Established cardiovascular disease, specifically a prior heart attack, stroke, or symptomatic peripheral arterial disease
What will it cost on the PBS? If listed, eligible patients would pay approximately $25 per script (general) or $7.70 per script (concession card holders), based on the January 2026 co-payment rates. This represents a saving of over $4,000 per year compared to the current private prescription cost.
When is the PBS listing expected? Based on historical timelines for other medications, PBS listing typically takes 6 to 18 months after a positive PBAC recommendation. A possible listing date in late 2026 or early 2027 has been suggested by industry analysts, but no official date has been confirmed.
If you do not meet the PBS criteria but still qualify for Wegovy under the broader TGA indications, you will continue to pay the private prescription price.
How to Get a Wegovy Prescription in Australia
You do not need a specialist referral to get a Wegovy prescription. Any registered Australian GP can prescribe it after conducting a clinical assessment.
Here is the typical prescription pathway:
Step 1: Book a consultation. You can see your regular GP in person, or book an online telehealth consultation with a registered doctor. Telehealth consultations are particularly convenient for patients in regional areas or those who prefer a private, remote appointment.
Step 2: Clinical assessment. Your doctor will assess your BMI, medical history, current medications, and any existing health conditions. Wegovy is TGA-approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, or high cholesterol.
Step 3: Prescription and dispensing. If your doctor determines that Wegovy is appropriate for you, they will issue a private prescription. You can have it dispensed at any pharmacy that stocks the medication. Many pharmacies can order it within 7 to 14 days if it is not currently in stock. Some online pharmacies and telehealth platforms offer home delivery.
Step 4: Follow-up appointments. Your prescriber will schedule regular follow-up consultations to monitor your response, manage any side effects, and adjust your treatment plan. These check-ins are typically every 4 to 8 weeks during the dose escalation period, and every 3 to 6 months once you are on the maintenance dose.
At HolisticChem, our pharmacists can answer your questions about Wegovy availability, storage requirements, and how the dose escalation schedule works in practice. If you already have a prescription, you can upload it and have your medication dispensed with delivery available across Australia.
What Are the Common Side Effects of Wegovy?
The most commonly reported side effects of Wegovy are gastrointestinal. Clinical trial data from the STEP programme show that these side effects are most frequent during the dose escalation period and tend to reduce over time as the body adjusts to the medication.
Nausea (reported by approximately 44% of participants in clinical trials, typically mild to moderate)
Diarrhoea (approximately 30% of participants)
Vomiting (approximately 24% of participants)
Constipation (approximately 24% of participants)
Abdominal pain (approximately 20% of participants)
The 16-week dose escalation schedule is specifically designed to minimise these effects by allowing your body to adjust gradually. Your prescribing doctor will advise you on managing any side effects and may adjust the escalation timing if needed.
In late 2025, the TGA issued a safety advisory for all GLP-1 receptor agonist medications regarding a potential risk of suicidal thoughts and changes in mood or behaviour. The TGA advises patients to tell their healthcare professional immediately if they experience new or worsening depression, suicidal thoughts, or any unusual changes in mood or behaviour while taking these medications.
This is not a complete list of side effects. Your prescribing doctor will discuss the full risk profile with you during your consultation and provide the Consumer Medicine Information (CMI) document for Wegovy.
How Does Wegovy Compare to Ozempic and Mounjaro on Cost?
Patients researching weight loss medications in Australia frequently compare three options: Wegovy, Ozempic, and Mounjaro. Here is a snapshot of how they compare on cost and key characteristics:
| Wegovy | Ozempic | Mounjaro | |
|---|---|---|---|
| Active ingredient | Semaglutide 2.4 mg | Semaglutide 1 mg | Tirzepatide |
| TGA indication | Weight management | Type 2 diabetes | T2D + weight management |
| Monthly cost (private) | $350 to $500 | $130 to $200 | $345 to $645 |
| PBS listed? | No (recommended) | Yes (T2D only) | No |
| Average weight loss | ~15 to 17% | ~10 to 12% | ~21% |
| Mechanism | GLP-1 agonist | GLP-1 agonist | Dual GIP + GLP-1 |
Ozempic is the most affordable option on the PBS for patients with type 2 diabetes, costing approximately $42 per script with the subsidy. However, prescribing Ozempic off-label solely for weight loss is not covered by the PBS, and the cost is $130 to $200 per month privately. Mounjaro showed greater average weight loss in clinical trials (approximately 21% at the highest dose) but is not PBS listed for any indication and costs $345 to $645 per month, depending on the dose.
Your prescribing doctor will help you determine which medication is most appropriate based on your health profile, goals, and budget. For a detailed side-by-side comparison, read our guide to Mounjaro vs Wegovy in Australia.
Are There Ways to Reduce the Cost of Wegovy in Australia?
While Wegovy remains a private prescription medication, several strategies may help reduce your out-of-pocket costs:
Check your private health insurance policy. Some mid-tier and top-tier policies may reimburse a portion of the medication cost. Coverage varies significantly between insurers and policy types, so contact your insurer directly to confirm whether Wegovy is covered under your plan.
Compare pharmacy prices. Pricing varies between pharmacies, and some discount pharmacies or online dispensaries may offer lower prices than independent pharmacies. Always compare at least two or three options before filling your prescription.
Ask about multi-month prescriptions. Some prescribers can issue longer prescriptions, which may reduce dispensing fees over time. Confirm with your pharmacist whether storage requirements (Wegovy must be refrigerated) allow for this approach.
Monitor the PBS timeline. If you meet the recommended PBS eligibility criteria (BMI 35+ with established cardiovascular disease), the subsidy could reduce your cost to approximately $25 per script once the listing is finalised.
Telehealth platforms may offer bundled pricing. Some telehealth providers include the consultation fee in the monthly medication cost, which can simplify budgeting.
HolisticChem is committed to helping patients access their prescribed medications at the best available price. If you have questions about cost, availability, or how to manage your Wegovy prescription, speak with one of our pharmacists on 03 8204 6600.
Important Things to Know Before Starting Wegovy
Compounded semaglutide is not a legal alternative. Since October 2024, compounded semaglutide and tirzepatide have been prohibited from being prescribed or dispensed in Australia. Only TGA-registered products (Wegovy, Ozempic, Mounjaro) may be supplied. HolisticChem does not compound or supply unapproved semaglutide.
Wegovy requires refrigeration. The pre-filled pens must be stored at 2 to 8 degrees Celsius. Once in use, a pen can be kept at room temperature (below 30 degrees Celsius) for up to 28 days.
Weight management is most effective with lifestyle support. Clinical guidelines recommend combining medication with dietary changes, physical activity, and behavioural support for the best long-term outcomes. Your prescribing doctor or pharmacist can help connect you with additional support.
Stopping the medication may lead to weight regain. Research indicates that appetite suppression and metabolic effects diminish after discontinuing GLP-1 medications. Discuss a long-term treatment strategy with your doctor.
Next Steps: Getting Started with Wegovy
Wegovy offers a clinically proven pathway for medically supervised weight loss in Australia. The cost ranges from $350 to $500 per month on a private prescription, with PBS subsidisation potentially on the horizon for patients with established cardiovascular disease and obesity.
The most important step is a conversation with a qualified prescriber who can assess your eligibility, explain the dose escalation schedule, and help you understand what to expect from treatment. If you have questions about Wegovy, weight management options, or prescription dispensing, our pharmacists at HolisticChem are here to help.
Call us on 03 8204 6600 or message us on WhatsApp at 0403 545 543 to speak with a pharmacist. You can also book a consultation through our telehealth partner at holisticahealth.com.au to get started.
Frequently Asked Questions About Wegovy Cost in Australia
How much does Wegovy cost per month in Australia?
Wegovy costs between $350 and $500 per month at the 2.4 mg maintenance dose on a private prescription. During the first 16 weeks of dose escalation, monthly costs start lower at approximately $270 to $350. The exact price depends on your pharmacy, location, and whether you are using a telehealth platform.
Is Wegovy covered by the PBS in Australia?
Not yet. The PBAC recommended Wegovy for PBS listing in January 2026, but the listing has not been finalised. Price negotiations between the Australian Government and Novo Nordisk are underway. If listed, eligible patients with a BMI of 35 or greater and established cardiovascular disease could pay approximately $25 per script.
Do I need a specialist referral to get Wegovy?
No. Any registered Australian GP can prescribe Wegovy after conducting a clinical assessment of your BMI, medical history, and current medications. You can see your GP in person or use a telehealth consultation service. No specialist referral is required.
Can I get compounded semaglutide instead of Wegovy to save money?
No. Since October 2024, compounded semaglutide and tirzepatide have been prohibited from being prescribed or dispensed in Australia. Only TGA-registered products such as Wegovy and Ozempic may be legally supplied. Any pharmacy or provider offering compounded semaglutide is operating outside Australian regulations.
Is Wegovy cheaper than Mounjaro in Australia?
At the maintenance dose, Wegovy is generally less expensive than Mounjaro. Wegovy costs $350 to $500 per month compared to $345 to $645 per month for Mounjaro (tirzepatide), depending on the dose. However, neither medication is currently PBS-listed for weight management. Your doctor will recommend the most appropriate option based on your health profile and treatment goals, not cost alone.